2022年生物仿制药报告（英）-英-36页_14mb

Introduction
Biosimilars are cost-effective alternatives to biologic medicines, approved by the FDA to provide safe and effective treatment at lower costs. Since the U.S. began using biosimilars in 2015, their adoption has grown significantly, driven by price reductions and policy supports, though challenges like payer barriers and knowledge gaps persist.

Biosimilars Basics

• Definition: High-quality, complex copies of reference biologics that must demonstrate similarity in structure and function.
• Benefits: Lower costs (15-30% less than originators), expanded access, and potential savings of $133 billion by 2025.
• Approval Process: Abbreviated FDA pathway under the Biologics Price Competition and Innovation Act, requiring rigorous safety and efficacy evaluations.

Market Growth
By 2022, 33 FDA-approved biosimilars were available, with oncology seeing the highest adoption (>60% market share). Biosimilar savings reached $8 billion in 2020, tripling previous years, due to increased competition and payer coverage improvements.

Provider and Payer Trends

• Providers: Oncologists express high comfort with biosimilars, while rheumatologists and ophthalmologists show hesitancy due to cost concerns and lack of real-world evidence. Diabetes experts highlight potential for cost savings but note barriers in pharmacy substitution.
• Payers: Coverage has improved, with a strong correlation (97%) between biosimilar adoption and favorable payer policies; however, administrative hurdles like prior authorizations slow uptake.

Future Predictions for 2022
Biosimilars will expand into immunology, diabetes, and ophthalmology, with key developments including:

• Insulin biosimilars testing managed care strategies in the pharmacy benefit;
• Humira biosimilars intensifying competition in immunology;
• Increased focus on real-world evidence to build provider trust;
• Policy changes supporting biosimilar use through federal and state initiatives, aiming for broader market access and cost savings.

Conclusion
Biosimilars offer significant potential to reduce healthcare costs and improve patient access, but ongoing efforts are needed to address payer barriers, provider education gaps, and administrative challenges to fully realize their benefits.